Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
While the desire by some HIV-positive patients to take 'drug holidays' from their antiretroviral regimens in order to have a break from strict routines, high prescription costs, or med toxicities might seem reasonable, a new study indicates that taking time off antiretrovirals can more than double the risk of disease progression and death. Despite prior small studies that suggested treatment breaks might be an alternative to ongoing regimen adherence, this new study of the large-scale Strategies for Management of Antiretroviral Therapy cohort, which was reported in the November 30 edition of The New England Journal of Medicine, set back researchers' prior hypotheses that treatment breaks might be able to allow longtime patients to preserve some treatment options for later in their disease progression by delaying buildup of resistance to medications. The average CD4 count was lower by 206 for patients in the study arm who took breaks than for those on continuous treatment. Within two months the proportion of participants with interrupted treatment who had viral loads below 400 fell from 71.8% to 6%. And opportunistic infection or death (including death from non-HIV-related illness, such as heart, kidney, or liver disease) occurred in 120 participants in the interrupted-treatment arm versus 47 who had continuous treatment. In January 2006 a previous arm of the study was prematurely halted when its participants began showing higher rates of opportunistic infections and death when compared with the patients who received regular, ongoing therapy. In summarizing the latest results, study cochair Wafaa El-Sadr said, 'Quite unexpectedly our results show that interrupting therapy increases the risk of serious non-AIDS-related events. This is a major lesson learned for designing any HIV treatment trial. It is important to evaluate all causes of death, not just death from AIDS.' Cochair James Keaton added that while treatment might increase the risk of liver, heart, and kidney disease, 'the absence of treatment appears to increase the risk even more.'
From our Sponsors
Most Popular
The road to U=U: How science has been liberating HIV+ people for a decade
July 01 2026 12:05 PM
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
April 29 2026 3:32 PM
How to find an HIV-competent healthcare provider, according to advocates
May 19 2026 4:55 PM
Plus: Featured Video
Latest Stories
A New Once-Daily Pill to Treat HIV Just Got the FDA’s Green Light
August 31 2026 2:31 PM
Why affirming faith communities belong in the fight to end HIV
August 30 2026 8:00 AM
Navigating a new HIV diagnosis? Advocates say community is key
August 25 2026 3:33 PM
Gay Wine Weekend toasts 15 years of raising funds for HIV
August 25 2026 11:00 AM
A new HIV diagnosis doesn't have to be nerve-wracking. Advocates share their advice
July 30 2026 12:01 PM
Zero HIV Stigma Day: The epidemic we still choose to ignore
July 21 2026 7:00 AM
National HIV Prevention Day: Awareness is my superpower
July 17 2026 8:00 AM
Federal court clarifies that people with HIV can join the military again
June 03 2026 5:36 PM
Can a single infusion of immune cells suppress HIV for years?
May 11 2026 11:39 AM
National HIV advocacy group's CEO rejects claims of crisis
April 21 2026 5:14 PM
Beyond awareness: How youth leadership is reshaping the HIV response
April 10 2026 9:12 AM
Saving public health? AIDS United's new CEO has a plan
March 23 2026 9:48 AM
Struggling with daily HIV meds? Monthly shots may be the answer
March 20 2026 7:12 AM
Trending stories
Recommended Stories for You


































































